UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53

Journal of the National Cancer Institute

Volumn 88, Issue 14, 1996, Pages 956-965

  Wang, Qizhi ^a   Fan, Saijun ^b   Eastman, Alan ^c   Worland, Peter J ^a   Sausville, Edward A ^a   O'Connor, Patrick M ^b,d  

^a Division of Clinical Sciences   (United States)

^b Laboratory of Molecular Pharmacology   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CISPLATIN; CYCLIN B; MITOMYCIN C; PROTEIN KINASE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL SURVIVAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOMA CELL; MITOSIS; PROTEIN PHOSPHORYLATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CDC2 PROTEIN KINASE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; CYCLIN B; CYCLINS; DRUG SYNERGISM; FLOW CYTOMETRY; G2 PHASE; GAMMA RAYS; GENES, P53; HUMANS; IMMUNOBLOTTING; MITOTIC INDEX; MUTATION; PRECIPITIN TESTS; RADIATION DOSAGE; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0029895439     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.14.956     Document Type: Article

References (43)

1. O'Connor PM, Kohn KW. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol 1992;3:409-16.
2. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34.
3. Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci U S A 1982;79:2942-6.
4. Weinert TA, Hartwell LH. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 1988; 241:317-22.
5. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, et al. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 1993;268:8298-308.
6. Demarcq C, Bunch RT, Creswell D, Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 1994;5:983-93.
7. Yamashita K, Yasuda H, Pines J, Yasumoto K, Nishitani H, Ohtsubo M, et al. Okadaic acid, a potent inhibitor of type 1 and type 2A protein phosphatases, activates cdc2/H1 kinase and transiently induces a premature mitosis-like state in BHK21 cells. EMBO J 1990;13:4331-8.
8. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994;54:6115-21.
9. Guo XW, Th'ng JP, Swank RA, Anderson HJ, Tudan C, Bradbury EM, et al. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 1995;14:976-85.
10. Nakamura K, Antoku S. Enhancement of X-ray cell killing in cultured mammalian cells by the protein phosphatase inhibitor calyculin A. Cancer Res 1994;54:2088-90.
11. Tam SW, Schlegel R. Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell Growth Differ 1992;3:811-7.
12. Andreassen PR, Margolis RL. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proc Natl Acad Sci U S A 1992;89:2272-6.
13. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimota M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun 1986;135:397-402.
14. Tamaoki T, Nakano H. Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 1990;8:732-5.
15. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-92.
16. Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 1989;43:851-6.
17. Bernhard EJ, Maity A, Muschel RJ, McKenna WG. Increased expression of cyclin B1 mRNA coincides with diminished G2-phase arrest in irradiated HeLa cells treated with staurosporine or caffeine. Radiat Res 1994;140:393-400.
18. Abe K, Yoshida M, Usui T, Horinouchi S, Beppu T. Highly synchronized culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 1991;192:122-7.
19. Crissman HA, Gadbois DM, Tobey RA, Bradbury EM. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc Natl Acad Sci U S A 1991;88:7580-4.
20. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot 1987;40:1782-4.
21. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 1987;42:571-6.
22. Akinaga S, Nomura K, Gomi K, Okabe M, Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993;32:183-9.
23. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995;6:927-36.
24. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990;344:503-8.
25. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls [see comment citation in Medline]. Nature 1992;359:599-604.
26. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D. mik1 and weel cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 1991;64:111-22.
27. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membraneassociated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995;270:86-90.
28. Hoffmann I, Clarke PC, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2 - cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993;12:53-63.
29. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
30. O'Connor PM, Ferris DK, Hoffmann I, Jackman J, Draetta G, Kohn KW. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc Natl Acad Sci U S A 1994;91:9480-4.
31. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
32. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 1993;90:3988-92.
33. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
34. Lock RB. Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 1992;52:1817-22.
35. Morla AO, Draetta G, Beach D, Wang JY. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 1989;58:193-203.
36. Solomon MJ, Glotzer M, Lee TH, Philippe M, Kirschner MW. Cyclin activation of P34cdc2. Cell 1990;63:1013-24.
37. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 1991;10:3321-9.
38. Lorca T, Labbe JC, Devault A, Fesquet D, Dapony JP, Cavadore JC, et al. Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 1992;11:2381-90.
39. Pines J, Hunter T. Isolation of a human cyclin B cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989;58:833-46.
40. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643-8.
41. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, Groudine M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res 1995;55:1639-42.
42. Th'ng JP, Wright PS, Hamaguchi J, Lee MG, Norbury CJ, Nurse P, et al. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 1990;63:311-24.
43. Dezube BJ, Eder JP, Pardee AB, Phase I trial of escalating pentoxifylline dose with constant-infusion thiotepa. Cancer Res 1990;50:6806-10.